Access Bio is expanding its reach into Africa with its malaria rapid diagnostic test (RDT), following another supply contract signing with distribution firm Partnership for Supply Chain Management.
With the signing of the 1.3 billion won ($1.12 million) contract, Access Bio will provide its malaria rapid diagnostic test (RDT) to the continent. The recent deal is equivalent to about 4.4 percent of Access Bio’s sales, according to the firm.
“Access Bio is leading the malaria RDT business by winning large-scale orders based on its core competencies in the bidding market, such as superior quality of malaria diagnostic products, reasonable price, and delivery capability through a mass production system,” the company said.
Through its subsidiary - Access Bio Korea – the firm aims to expand production capacity and obtain the Prequalification (PQ) designation from the World Health Organization (WHO). It is also seeking to expand its market dominance in the public sector, a company official said.
Partnership for Supply Chain Management is a nonprofit organization established in the United States that supports strengthening the medical supply chain and improving the quality of medical care in underdeveloped and developing countries.
<© Korea Biomedical Review, All rights reserved.>